The distinctions between obesity-induced features occurring in the entire adipocyte population versus specific adipocyte subpopulations may explain the outstanding effectiveness of PPARγ agonists, such as thiazolidinediones (TZDs), in improving adipose function and glucose homeostasis37, surpassing the effects of other anti-inflammatory or anti-stress reagents43–45. Here, PPARG is linked to obesity due to melanocortin 4 receptor deficiency.